ArticleMicrobial cell factories2022
Biosynthesis of eriodictyol from tyrosine by Corynebacterium glutamicum.
Article in Microbial cell factories, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 36 citations in OpenAlex.
- Design and multidimensional optimization of cell-free system for efficient (2S)-naringenin production.Biodesign research · 2026Article
- Advanced applications of synthetic biology technology in biosynthesis of bioactive compounds from medicinal plants.Chinese herbal medicines · 2026Review
- Microbe-driven flavonoid biotransformation revealed by multi-omics analysis during Hua Feng Dan Yao Mu fermentation.Frontiers in microbiology · 2026Article
- Engineering of Corynebacterium glutamicum for the synthesis of aromatic compounds.Applied microbiology and biotechnology · 2025Review
- Tissue-specific biosynthesis and regulation of alkaloids, flavonoids, and terpenoids in fenugreek (Frontiers in plant science · 2025Article
- Expanding the application of tyrosine: engineering microbes for the production of tyrosine and its derivatives.Frontiers in bioengineering and biotechnology · 2025Review
- The Extraction, Biosynthesis, Health-Promoting and Therapeutic Properties of Natural Flavanone Eriodictyol.Nutrients · 2024Review
- Article
- Metabolic engineering ofMetabolic engineering communications · 2024Article
- Review of the Proteomics and Metabolic Properties ofMicroorganisms · 2024Review
- Metabolic Engineering ofMolecules (Basel, Switzerland) · 2024Review
- 4-Hydroxyphenylacetate 3-Hydroxylase (4HPA3H): A Vigorous Monooxygenase for VersatileInternational journal of molecular sciences · 2024Review
- Optimization of flavanonols heterologous biosynthesis inFrontiers in microbiology · 2024Article
- Eriodictyol Alleviated LPS/D-GalN-Induced Acute Liver Injury by Inhibiting Oxidative Stress and Cell Apoptosis via PI3K/AKT Signaling Pathway.Nutrients · 2023Article
- Advances in 4-Hydroxyphenylacetate-3-hydroxylase Monooxygenase.Molecules (Basel, Switzerland) · 2023Review
- Optimized De Novo Eriodictyol Biosynthesis inInternational journal of molecular sciences · 2023Article
- Flavonoid Production: Current Trends in Plant Metabolic Engineering and De Novo Microbial Production.Metabolites · 2023Review
- Engineered living materials for the conversion of a low-cost food-grade precursor to a high-value flavonoid.Frontiers in bioengineering and biotechnology · 2023Article
- Genomic profiling of WRKY transcription factors and functional analysis of CcWRKY7, CcWRKY29, and CcWRKY32 related to protoberberine alkaloids biosynthesis inFrontiers in genetics · 2023Article
- Synthetic biology tools for engineeringComputational and structural biotechnology journal · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
Abstract
backgroundEriodictyol is a bioactive flavonoid compound that shows potential applications in medicine development and food processing. Microbial synthesis of eriodictyol has been attracting increasing attention due to several benefits. In this study, we employed a GRAS strain Corynebacterium glutamicum as the host to produce eriodictyol directly from tyrosine.
resultsWe firstly optimized the biosynthetic module of naringenin, the upstream intermediate for eriodictyol production, through screening of different gene orthologues. Next, to improve the level of the precursor malonyl-CoA necessary for naringenin production, we introduced matB and matC from Rhizobium trifolii into C. glutamicum to convert extracellular malonate to intracellular malonyl-CoA. This combinatorial engineering resulted in around 35-fold increase in naringenin production from tyrosine compared to the initial recombinant C. glutamicum. Subsequently, the hpaBC genes from E. coli encoding 4-hydroxyphenylacetate 3-hydroxylase were expressed in C. glutamicum to synthesize eriodictyol from naringenin. Further optimization of the biotransformation process parameters led to the production of 14.10 mg/L eriodictyol.
conclusionsThe biosynthesis of the ortho-hydroxylated flavonoid eriodictyol in C. glutamicum was achieved for the first time via functional expression of E. coli hpaBC, providing a baseline strain for biosynthesis of other complex flavonoids. Our study demonstrates the potential application of C. glutamicum as a host microbe for the biosynthesis of value-added natural compounds from tyrosine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.